🔗 Share this article World Health Organization Raises Warning Over Severe Scarcity of Obesity Medications Fewer than 10% of individuals eligible to benefit from GLP-1 drugs like Wegovy have access to them, states the global health agency as it releases its inaugural guidance on the medications. With in excess of 1,000,000,000 individuals worldwide currently living with obesity, it is urging broader and more equitable access to GLP-1 medication. According to forecasts, in excess of 2,000,000,000 could be living with obesity by 2030 unless action is taken. "The latest guidelines affirms that excess weight is a lifelong illness that can be managed with comprehensive and continuous care," stated its chief Tedros Adhanom Ghebreyesus. High costs, insufficient output, and logistical bottlenecks are key hurdles to universal availability to the jabs that can help people shift significant weight, notes the organization. GLP-1 Therapy Scarcity Even under the present best projected scenario, the manufacturing of such drugs might only reach approximately 100 million people – less than 10% of eligible patients, as stated by the health organization. The advice encourages nations and manufacturers to increase access, by measures such as patent sharing. Exclusive production rights on the active ingredient – the main ingredient of Novo Nordisk's Wegovy – is due to expire in a number of countries in 2026. The Way Obesity Injections Work These medications replicate a biological compound to slow digestion, reduce hunger and enhance the sense of being full so individuals reduce food intake. People usually see weight reduction in the initial weeks of commencing the once-weekly jabs. Evidence indicates people may regain a significant portion after a year of stopping the drug, as their usual hunger return. Being above a healthy weight raises your risk for contracting medical conditions, like type 2 diabetes, heart disease, stroke, and some malignancies. Excess weight impacts people in countries worldwide and was associated with over three and a half million deaths worldwide in 2024, according to the health agency.
Fewer than 10% of individuals eligible to benefit from GLP-1 drugs like Wegovy have access to them, states the global health agency as it releases its inaugural guidance on the medications. With in excess of 1,000,000,000 individuals worldwide currently living with obesity, it is urging broader and more equitable access to GLP-1 medication. According to forecasts, in excess of 2,000,000,000 could be living with obesity by 2030 unless action is taken. "The latest guidelines affirms that excess weight is a lifelong illness that can be managed with comprehensive and continuous care," stated its chief Tedros Adhanom Ghebreyesus. High costs, insufficient output, and logistical bottlenecks are key hurdles to universal availability to the jabs that can help people shift significant weight, notes the organization. GLP-1 Therapy Scarcity Even under the present best projected scenario, the manufacturing of such drugs might only reach approximately 100 million people – less than 10% of eligible patients, as stated by the health organization. The advice encourages nations and manufacturers to increase access, by measures such as patent sharing. Exclusive production rights on the active ingredient – the main ingredient of Novo Nordisk's Wegovy – is due to expire in a number of countries in 2026. The Way Obesity Injections Work These medications replicate a biological compound to slow digestion, reduce hunger and enhance the sense of being full so individuals reduce food intake. People usually see weight reduction in the initial weeks of commencing the once-weekly jabs. Evidence indicates people may regain a significant portion after a year of stopping the drug, as their usual hunger return. Being above a healthy weight raises your risk for contracting medical conditions, like type 2 diabetes, heart disease, stroke, and some malignancies. Excess weight impacts people in countries worldwide and was associated with over three and a half million deaths worldwide in 2024, according to the health agency.